Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 31 -37 of 37 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


31.		A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				19 to 75				Other				FLUSALEM NCT00565981


32.		Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				17 and over				Other				3991 NCT00580034


33.		Allo Non-Myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				17 and over				Other				3768 NCT00578942

Last Modified: 6/5/2007 First Published: 2/18/2005


34.		Phase I Study of a Reduced Intensity Conditioning Regimen Comprising Alemtuzumab, Fludarabine, Melphalan, and Thiotepa Followed by Allogeneic Peripheral Blood Stem Cell Transplantation and LMB-2 Immunotoxin-Treated, Selectively-Depleted Donor T Cells in Patients With Hematologic Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 to 55				NCI				YALE-25971 6765, NCI-6765, NCT00104975


35.		Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Other				0204-157 NCT00161590

Last Modified: 9/1/2001 First Published: 7/1/2001


36.		Compassionate Use Program of Campath-1H in Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia (Summary Last Modified 09/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				CWRU-ILEX-1999 ILEX-CAM511-A1, NCI-G01-1977, NCT00021151

Last Modified: 8/31/2006 First Published: 4/7/2006


37.		Study of Nonmyeloablative Conditioning Comprising Fludarabine, Alemtuzumab, and Total-Body Irradiation Followed By T-Cell-Depleted Allogeneic Stem Cell Transplantation and Post-Transplantation Allogeneic T-Cell Infusion in Patients With Imatinib Mesylate-Resistant Chronic Phase Chronic Myelogenous Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Closed				4 to 75				NCI				OHSU-TPI-02032-L OHSU-414, OHSU-TPI-02030-L, NCT00416884

Select All on One Page


					< Previous 1 2 3 4

| | | | | | | |

A Service of the National Cancer Institute